USMLE Step 1 practice question: Cisplatin toxicity (ototoxicity, nephrotoxicity, hypomagnesemia): DNA cross-linking

USMLE Step 1Hematology/OncologyPharmacology

A 27-year-old man comes to the oncology clinic because of ringing in both ears and difficulty following conversations in noisy rooms for 1 week. Two months ago, he underwent radical inguinal orchiectomy for a testicular mass; pathologic examination showed embryonal carcinoma, and serum α-fetoprotein and β-hCG concentrations were elevated. A CT scan showed enlarged retroperitoneal lymph nodes, and he was started on a three-drug combination chemotherapy regimen; he has now completed three cycles. He also reports leg cramps and generalized weakness. He has no other history of serious illness. He does not smoke cigarettes or drink alcohol. His temperature is 37.0°C (98.6°F), pulse is 88/min, respirations are 14/min, and blood pressure is 118/72 mm Hg. The lungs are clear to auscultation. There is no rash, skin hyperpigmentation, or nail change. Audiometry shows bilateral sensorineural hearing loss at frequencies above 4000 Hz. Laboratory studies show: Hemoglobin 11.2 g/dL Leukocyte count 4,100/mm3 Platelet count 168,000/mm3 K+ 3.1 mEq/L Mg2+ 1.0 mg/dL Creatinine 1.6 mg/dL (0.9 mg/dL before chemotherapy) Pulmonary function testing shows a normal diffusing capacity for carbon monoxide (DLCO).

The drug most likely responsible for this patient's hearing loss exerts its antineoplastic effect by which of the following mechanisms?

  1. Inhibition of topoisomerase II
  2. Generation of free radicals that cause DNA strand breaks
  3. Inhibition of dihydrofolate reductase
  4. Formation of intrastrand DNA cross-links
  5. Inhibition of microtubule polymerization
Show answer and explanation

Correct answer: D. Formation of intrastrand DNA cross-links

This patient with a nonseminomatous germ cell tumor is most likely receiving BEP (bleomycin, etoposide, and cisplatin), the standard regimen for advanced testicular cancer. His new bilateral tinnitus and high-frequency sensorineural hearing loss, acute kidney injury, and renal magnesium and potassium wasting are characteristic toxicities of cisplatin.

Cisplatin is a platinum compound. Inside cells, where the chloride concentration is low, its chloride ligands are replaced by water (aquation), producing a reactive species that binds the N7 position of guanine. It forms predominantly 1,2-intrastrand cross-links between adjacent purines, as well as some interstrand cross-links, which distort the DNA helix, block replication and transcription, and trigger apoptosis. Its action is cell cycle–nonspecific.

Cisplatin toxicities: • Nephrotoxicity: accumulation in proximal tubule cells causes acute tubular injury with renal Mg2+ wasting (hypomagnesemia), which in turn worsens hypokalemia. Prevention: vigorous saline hydration (chloride diuresis); amifostine, a free-radical scavenger, is an option. • Ototoxicity: reactive oxygen species damage outer hair cells in the basal turn of the cochlea, producing irreversible high-frequency sensorineural hearing loss and tinnitus. Sodium thiosulfate is approved to reduce ototoxicity in children with localized, nonmetastatic solid tumors. • Peripheral sensory neuropathy and severe nausea and vomiting (highly emetogenic).

High-yield summary: Cisplatin (like carboplatin and oxaliplatin) cross-links DNA; cisplatin causes nephrotoxicity with hypomagnesemia, ototoxicity, peripheral neuropathy, and severe emesis.

Why the other options are wrong

  • A. Inhibition of topoisomerase II — Etoposide inhibits topoisomerase II, causing double-strand DNA breaks. Its main toxicities are myelosuppression, alopecia, mucositis, and secondary acute myeloid leukemia; it does not cause ototoxicity or renal magnesium wasting.
  • B. Generation of free radicals that cause DNA strand breaks — Bleomycin binds iron and generates free radicals that cause DNA strand breaks. Its characteristic toxicities are pulmonary fibrosis (with decreased DLCO) and skin changes (hyperpigmentation, flagellate dermatitis); it causes minimal myelosuppression and no hearing loss. This patient's DLCO is normal.
  • C. Inhibition of dihydrofolate reductase — Methotrexate inhibits dihydrofolate reductase. It causes myelosuppression and mucositis (rescued by leucovorin), hepatotoxicity, and pneumonitis, and high doses can cause crystal nephropathy, but it is not ototoxic and is not part of standard germ cell tumor regimens.
  • E. Inhibition of microtubule polymerization — Vinca alkaloids (vinblastine, vincristine) bind β-tubulin and inhibit microtubule polymerization, arresting cells in M phase. Vinblastine causes myelosuppression, and vincristine causes peripheral neuropathy and constipation; neither causes ototoxicity or renal Mg2+ wasting.

Key point

Cisplatin forms DNA cross-links (mainly intrastrand) and characteristically causes ototoxicity (high-frequency sensorineural hearing loss), nephrotoxicity with hypomagnesemia, and peripheral neuropathy.

Memory hook

Platinum handcuffs adjacent guanines together (intrastrand cross-links). Heavy metal, heavy toll: ears (high-tone hearing loss), kidneys (↓Mg²⁺), nerves, relentless vomiting.

Share: Telegram WhatsApp X LinkedIn

Practice like this every day

15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.

Play free

More free questions in this system

Warfarin-induced skin necrosis: early protein C depletionUSMLE Step 1 · Hematology/OncologyTumor lysis syndrome: rasburicase mechanism and G6PD deficiencyUSMLE Step 1 · Hematology/OncologyHigh-risk febrile neutropenia after AML induction: empiric IV cefepime within 1 hourUSMLE Step 2 CK · Hematology/Oncology

All free questions →